#### 1 The aconitate decarboxylase 1/itaconate pathway modulates immune dysregulation 2 and associates with cardiovascular disease markers in SLE.

3

4 Eduardo Patiño-Martinez<sup>1</sup>, Shuichiro Nakabo<sup>1</sup>, Kan Jiang<sup>2</sup>, Carmelo Carmona- Rivera<sup>1</sup>, 5 Wanxia Li Tsai<sup>3</sup>, Dillon Claybaugh<sup>1</sup>, Zu-Xi Yu<sup>4</sup>, Aracely Romero<sup>1</sup>, Eric Bohrnsen<sup>5</sup>, Benjamin Schwarz<sup>5</sup>, Miguel A. Solís-Barbosa<sup>6</sup>, Luz P. Blanco<sup>1</sup>, Mohammad Naqi<sup>7</sup>, Yenealem 6 7 Temesgen-Oyelakim<sup>7</sup>, Michael Davis<sup>7</sup>, Zerai Manna<sup>7</sup>, Nehal Mehta<sup>4</sup>, Faiza Naz<sup>8</sup>, Stephen Brooks<sup>8</sup>, Stefania dell'Orso<sup>8</sup>, Sarfaraz Hasni<sup>7</sup> and Mariana J. Kaplan<sup>1</sup>. 8 9 <sup>1</sup>Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, Maryland, USA;<sup>2</sup> Biodata 10 Mining and Discovery Section, NIAMS/NIH; <sup>3</sup> Translational Immunology Section, NIAMS/NIH; 11 <sup>4</sup>National Heart, Lung, and Blood Institute (NHLBI), NIH. <sup>5</sup>Protein & Chemistry Section, 12 13 Research Technologies Branch, National Institute of Allergy and Infectious Diseases (NIAID), 14 NIH, Hamilton, MT, USA. <sup>6</sup>Department of Molecular Biomedicine, Centro de Investigación y de Estudios Avanzados del I.P.N, 07360 Mexico City, Mexico; <sup>7</sup>Lupus Clinical Trials Unit, 15 NIAMS/NIH; <sup>8</sup>Office of Science and Technology, NIAMS/NIH. 16 17 Correspondence and reprint requests: 18 Mariana J. Kaplan, M.D. 19 Systemic Autoimmunity Branch; NIAMS/National Institutes of Health 20 10 Center Drive; 12N248C 21 Bethesda, MD 20892

- 22 Phone: 301-496-0517
- 23 Email: mariana.kaplan@nih.gov
- 24 There are no conflicts of interest.
- 25 Funding: Supported by the Intramural Research Program at NIAMS/NIH (ZIA AR041199).

26 27	What	is already known on this topic
27 28 29 30 31 32 33 34	•	Aconitate Decarboxylase 1 (ACOD1) is an enzyme involved in the synthesis of itaconate, a metabolite generated during the Krebs cycle. Itaconate has been identified as an immunomodulatory molecule ACOD1/Itaconate has been studied in the context of various inflammatory and autoimmune diseases, including sepsis, inflammatory bowel disease and rheumatoid arthritis. In these conditions, dysregulation of itaconate metabolism has been associated with altered immune responses and disease progression.
35 36	What	this study adds
37	mat	
38	1.	Upon stimulation with lupus-relevant stimuli, ACOD1 expression is induced in
39 40	2.	IN an induced mouse model of lupus, ACOD1 knockout (Acod1-/-) mice exhibit
41 42		exacerbated lupus-like symptoms, implicating dysregulation of this pathway in the induction and severity of autoimmunity features.
43 44 45	3.	Itaconate serum levels are decreased in SLE patients, compared to healthy individuals. This decrease is associated with specific perturbed cardiometabolic parameters and subclinical atherosclerosis, indicating that modulating
46		dysregulation of the itaconate pathway could have therapeutic benefits in this
47 18		disease.
40 49		
50 51	How	this study might affect research, practice or policy
51 52	•	Given its immunomodulatory effects, ACOD1/itaconate and its derivatives may
53 54 55		may also serve as putative biomarkers of cardiovascular risk in this disease.

#### 56 Abstract

#### 57 **Objective**

The Krebs cycle enzyme Aconitate Decarboxylase 1 (ACOD1) mediates itaconate synthesis in myeloid cells.. Previously, we reported that administration of 4-octyl itaconate abrogated lupus phenotype in mice. Here, we explore the role of the endogenous ACOD1/itaconate pathway in the development of murine lupus as well as their relevance in premature cardiovascular damage in SLE.

63

#### 64 Methods

We characterized Acod1 protein expression in bone marrow-derived macrophages and human monocyte-derived macrophages, following a TLR7 agonist (imiquimod, IMQ). Wild type and Acod1<sup>-/-</sup> mice were exposed to topical IMQ for 5 weeks to induce an SLE phenotype and immune dysregulation was quantified. Itaconate serum levels were quantified in SLE patients and associated to cardiometabolic parameters and disease activity.

71

#### 72 **Results**

ACOD1 was induced in mouse bone marrow-derived macrophages (BMDM) and human monocyte-derived macrophages following in vitro TLR7 stimulation. This induction was partially dependent on type I Interferon receptor signaling and specific intracellular pathways. In the IMQ-induced mouse model of lupus, ACOD1 knockout (*Acod1-<sup>/-</sup>*) displayed disruptions of the splenic architecture, increased serum anti-dsDNA and proinflammatory cytokine levels, enhanced kidney immune complex deposition and

proteinuria, when compared to the IMQ-treated WT mice. Consistent with these results, *Acod1-<sup>1-</sup>* BMDM exposed to IMQ showed higher proinflammatory features in vitro. Itaconate levels were decreased in SLE serum compared to healthy control sera, in association with specific perturbed cardiometabolic parameters and subclinical vascular disease.

84

### 85 Conclusion

These findings suggest that the ACOD1/itaconate pathway plays important immunomodulatory and vasculoprotective roles in SLE, supporting the potential therapeutic role of itaconate analogs in autoimmune diseases.

#### 90 INTRODUCTION

91 Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder that can affect 92 multiple organs and systems in the body. It is more prevalent in women and can present 93 with a broad range of clinical symptoms and signs. The causes of SLE are complex and involve a combination of genetic, epigenetic and environmental factors that trigger a 94 95 breakdown of immune tolerance. This leads to the activation of autoreactive lymphocytes, production of autoantibodies and innate immune dysregulation. The type I Interferon (IFN) 96 97 pathway, myeloid aberrant responses (including enhanced synthesis of neutrophil 98 extracellular traps (NETs)) and defective clearance of immune complexes and dead cells. 99 all contribute to loss of tolerance, tissue damage and organ dysfunction in SLE (1, 2). Part 100 of this dysregulation is driven by activation of intracellular sensors of nucleic acids, sch 101 as Toll-like receptor-7 (TLR7). Furthermore, SLE patients have accelerated vascular 102 damage that predisposes to premature heart attacks and stroke, aphenomenon 103 considered to be driven by immune dysregulation (3, 4).

104

Several studies indicate that mitochondrial dysfunction, increased oxidative stress and other metabolic pathway alterations in both the innate and adaptive immune cells play a crucial role in the development and severity of SLE and its associated organ damage (<u>5</u>). Thus, pharmacological interventions targeting immunometabolism have emerged as potential approaches to managing SLE (6).

110

111 Aconitate decarboxylase 1 (ACOD1) is a mitochondrial enzyme that plays a vital role in 112 cellular metabolism, oxidative stress and inflammatory responses (<u>7</u>). It mediates

itaconate synthesis by decarboxylating cis-aconitate and can either promote or inhibit inflammation ( $\underline{8}$ ,  $\underline{9}$ ). The ACOD1/itaconate axis is activated under stress conditions, including infections, and downstream of TLRs or cytokine stimulation in macrophages, monocytes and dendritic cells (DCs) (<u>10</u>).

117

The development of the ACOD1 knockout mice (Acod1<sup>-/-</sup>), which lacks the ability to 118 119 produce itaconate, helped elucidate that the endogenous ACOD1/itaconate axis 120 regulates succinate levels, mitochondrial respiration and cytokine production during 121 macrophage activation (11). Particularly, ACOD1 deficiency and a decrease in itaconate 122 production have proven to be deleterious in several acute and chronic inflammatory 123 diseases (12). For example, in response to viral or bacterial infections, Acod1<sup>-/-</sup> mice 124 generally have poorer survival, inflammatory cytokine burst, uncontrolled neutrophil 125 recruitment and immune-mediated tissue damage compared to wild-type (WT) mice (13). 126 In addition, ACOD1 modulates macrophage polarization in the tumor microenvironment, 127 promoting cancer progression (14). Along with these reports, ACOD1 deficiency has been associated with a worse disease phenotype in a mouse model of psoriasis induced by the 128 129 TLR7 agonist imiquimod (IMQ) (15). Further, in a bleomycin-induced pulmonary fibrosis 130 model, ACOD1 deficiency promotes persistent fibrosis with increased expression of 131 profibrotic genes (12).

132

Similar to *Acod1<sup>-/-</sup>* models, esterified derivatives of itaconate, 4-octyl itaconate (4-OI) and
dimethyl itaconate (DI), are commonly used to mimic ACOD1/Itaconate biological effects
in vitro and in vivo (<u>16</u>). Indeed, 4-OI has beneficial effects in numerous in vivo animal

136 models (17-19), including our recent findings that this compound attenuates immune 137 dysregulation and organ damage in a mouse model of spontaneous lupus (20). In human 138 studies, treatment of lupus PBMCs with 4-OI decreases the production of pro-139 inflammatory cytokines (21), while serum itaconate levels are decreased in SLE (22). 140 Taken together, these reports suggest that the ACOD1/Itaconate pathway could be 141 important in the development and perpetuation of SLE. Therefore, we have now 142 investigated the contribution of endogenous itaconate synthesis to SLE, including its 143 putative role in the development and perpetuation of clinical symptoms and immune 144 dysregulation in the TLR7-induced lupus IMQ model (23). Using a well characterized 145 human SLE cardiovascular cohort, we also investigated whether there is an association 146 between itaconate and subclinical vascular disease in SLE.

#### 148 **Results**

149

# ACOD1 is induced in murine and human macrophages following TLR7 in vitrostimulation.

152 Givne that, to our knowledge, there were no previous reports on whether TLR7 153 engagement (a lupus-relevant pathway) would induce ACOD1, we performed an in vitro 154 time-course on WT and Acod1<sup>-/-</sup> bone marrow-derived macrophages (BMDM) following 155 incubation with IMQ. Western blot analysis showed that ACOD1 protein expression was 156 evident at 12 h of treatment and persisted at 24 h (Fig. 1a). As expected, ACOD1 was 157 not detected in the Acod1-- BMDM. Based on the overall late induction of ACOD1 protein 158 and that type I IFNs are induced by IMQ treatment, we investigated whether the ACOD1 159 induction relied on type I IFN signaling. To this end, ACOD1 induction was evaluated in BMDM deficient in type I IFN receptor  $\alpha$ -1 (*Ifnar1*<sup>-/-</sup>) following in vitro treatment with IMQ 160 161 for 12 and 24 hours. In the absence of the IFNAR1, ACOD1 induction was significantly 162 decreased, suggesting that ACOD1 expression with TLR7 activation is partially 163 dependent on signaling through IFNAR1 (Fig. 1b). RNA-seq analysis of BMDM treated 164 with IMQ for 12h (GSE250384) showed that Acod1 is among the 50 differentially 165 expressed genes in response to TLR7 stimulation (Fig. 1c). Gene ontology analysis of 166 these IMQ-treated BMDM showed enrichment of pathways associated to cytokines, 167 inflammation, innate immune response, neutrophil degranulation, phagocytosis, and type 168 II IFNs (Fig. 1d). Furthermore, the gene expression analysis suggested metabolic 169 rewiring in IMQ-treated BMDM. Specifically, we observed that, under basal conditions, 170 macrophages express higher levels of genes associated with lipid catabolic metabolism,

whereas after TLR7 stimulation they switched to pathways of lipid biosynthetic
metabolism and express higher levels of genes related to the synthesis of prostaglandins
(Fig. 1e).

174

175 We proceeded to validate these findings in human healthy control monocyte-derived 176 macrophages. Monocytes were differentiated into M1-like and M2-like using GM-CSF and M-CSF, respectively, then treated with IMQ in vitro for 3 and 12 hours. Similar to BMDM, 177 ACOD1 was induced after 12 hours of IMQ treatment (Fig. 2a), but only in the M-CSF 178 179 (M2)-derived macrophages, perhaps explained by previous observations that GM-CSF-180 derived macrophages lack TLR7 expression (24) (Fig. 2b). Next, we used specific 181 inhibitors of different signaling pathways reported to be activated downstream of TLR7 stimulation(25). We found that NF-κB, p38, JNK, ERK1/2, JAK-STAT and STING 182 183 activation are involved in ACOD1 induction after TLR7 activation (Fig 2c-d). In addition, 184 we observed that the induction of ACOD1 mediated by TLR7 activation was decreased 185 after using a histone acetyl transferase II inhibitor, suggesting that epigenetic 186 modifications are also involved in ACOD1 induction after TLR7 activation. Taken together, 187 these results indicate that ACOD1 is induced after TLR7 activation in human and mouse 188 macrophages, in a process that involves type I IFN signaling and canonical pathways of 189 inflammatory cytokine synthesis.

190

191 **ACOD1** deficient mice develop splenic morphological changes.

192 To further investigate the potential contribution of the endogenous ACOD1/itaconate 193 pathway in lupus autoimmunity, we treated WT and *Acod1-/-* mice epicutaneously with

IMQ for 5 weeks. This is a well- established model of induced lupus that is characterized by splenomegaly, type I IFN induction, anemia, renal immune complex deposition, endothelial dysfunction and immune dysregulation (23). For every clinical and most immunologic assessments, we observed that, in the absence of TLR7 stimulation, *Acod1*-/- and WT mice did not show any significant differences.

199

200 Mice treated with IMQ (WT and Acod1<sup>-/-</sup>) developed an autoimmune phenotype consistent 201 with lupus, and also developed anemia and leukocytosis, as previously described (23) 202 (Fig. 1S). Following IMQ, there were no significant differences in mortality rates 203 comparing WT and Acod1<sup>-/</sup> (Fig. 3a). Similarly, no differences between treated Acod1<sup>-/</sup> 204 and WT were detected in serum chemistry (glucose, creatinine, electrolytes). (Table 1S). In contrast, following IMQ treatment, Acod1<sup>-/-</sup> mice displayed lower spleen;body weight 205 206 ratios compared to WT imiquimod-treated (Fig. 3b) Morphologically, IMQ-treated Acod1-207 <sup>1</sup> mice displayed marked splenic congestion of the red pulp and atrophy of the white pulp 208 when compared to IMQ-treated WT mice, similar to what has been reported in human 209 SLE (26) (Fig. 3c). Splenocytes from untreated and IMQ-treated WT and Acod1<sup>-/-</sup> mice 210 were analyzed by flow cytometry to quantify immune cell populations. In the IMQ-treated 211 mice, Acod1<sup>-/-</sup> displayed higher percentages of naïve B cells compared to the WT mice, 212 but no changes in the percentage of total B cells, plasma cells, monocytes, DCs, 213 neutrophils (Fig. 3d) and T cells (Fig. 2S). No differences were found in levels of various 214 type I IFN-regulated genes nor in other genes associated to inflammatory pathways (II1b, 215 *II18, II6, TIr7 and Tnf*) in splenocytes (Fig. 3S) Taken together, results indicate that lack 216 of ACOD1 promotes changes in the splenic architecture but no significant changes in the

composition of splenic immune cell types or in regulation of inflammatory genes in amouse model of lupus.

219

# Acod1<sup>-/-</sup> mice have higher levels of serum autoantibodies and kidney immune complex deposition in TLR7-induced lupus.

222 Compared to WT mice, Acod1<sup>-/-</sup> mice exposed to IMQ displayed significantly higher levels 223 of serum anti-dsDNA autoantibodies, while anti-Sm, anti-RNP and total IgG levels were 224 no different from those in IMQ-treated WT mice (Fig. 4a). In addition, IMQ-treated Acod1<sup>-</sup> 225 <sup>1-</sup> mice developed significantly increased glomerular immune complex deposition 226 compared to IMQ-treated WT mice (Fig. 4b-c). While this specific mouse model of lupus 227 is not characterized by nephrotic-range proteinuria or end-stage renal disease (27), IMQ-228 treated Acod1<sup>-/-</sup> mice had increased albumin:creatinine ratios in urine compared to IMQ-229 treated WT mice (Fig. 4d), indicating that renal function was more impaired in Acod1-/-230 mice exposed to IMQ. Consistent with these results, we found that, in kidneys from 231 NZB/W F1 mice, a model of spontaneous severe lupus that we had previously shown 232 improves with exogenous analogs of itaconate, Acod1 mRNA expression was decreased 233 as disease progressed (10 to 30 week-old mice), suggesting that ACOD1 absence may 234 modulate the development and progression of lupus nephritis (Fig. 4e).

235

As endothelial dysfunction and vasculopathy are hallmarks of both murine (<u>28</u>) and human SLE (<u>3</u>, <u>4</u>), we evaluated endothelium-dependent vasorelaxation in precontracted thoracic aortas following exposure to graded concentrations of acetylcholine. IMQ-treated  $Acod1^{-/-}$  mice showed similar perturbations in endothelium-dependent vasorelaxation

when compared to IMQ-treated WT mice (Fig. 4S), suggesting that lack of ACOD1 does
not modulate lupus vasculopathy in mice.

242

As expected, IMQ-treated mice had significant elevation of various pro-inflammatory cytokines compared to the non-treated animals (**Fig. 5S**). Of note, IL-6 serum levels were significantly increased in the IMQ-treated *Acod1*<sup>-/-</sup> mice compared to the IMQ-treated WT mice, while CCL5 and VEGFA were decreased (**Fig. 5**). Overall, results indicate that ACOD1 modulates pathogenic autoAb synthesis, kidney immune complex deposition and renal injury, and systemic inflammatory cytokine production in lupus-prone mice.

249

#### 250 Acod1<sup>-/-</sup> modulates myeloid cell responses following TLR stimulation.

251 The ACOD1/itaconate pathway was previously reported to modulate cytokine production 252 in mouse and human macrophages after stimulation with other TLRs or with cytokines (11). To investigate the role of ACOD1 pathway on cytokine/chemokine production 253 254 following TLR7 stimulation, Acod1<sup>-/-</sup> BMDM were treated with IMQ for 12 hours. gPCR 255 analysis revealed a significant increase in cxc/2 mRNA levels in IMQ-treated Acod1-/-256 compared to IMQ-treated WT BMDM (Fig. 6a), but no significant differences in *il6*, *il1b*, 257 ccl2, cxcl9, il18, irf7 and mx1 mRNA levels. Western blot analysis of WT and Acod1--258 BMDM treated with IMQ revealed an increase in pro-IL-1 $\beta$  intracellular levels (Fig. 6b) and in the secretion of IL-1 $\beta$  and IL-6 (Fig. 6c). Consistent with these results, Acod1<sup>-/-</sup> 259 260 peritoneal mouse macrophages treated for 12 hours in vitro with IMQ showed higher 261 levels of IL-1 $\beta$  and caspase-1 activation (Fig. 6S). These results support previous 262 observations that the ACOD1-itaconate pathway regulates IL-1ß processing and IL-6

production after activation with other TLRs (TLR4) (<u>11</u>) and suggest that this pathway is
 implicated in downregulating inflammatory cytokine synthesis triggered by endosomal
 TLRs.

266

267 To further understand the metabolic rewiring induced by ACOD1, we evaluated 268 mitochondrial function in macrophages by measuring the oxygen consumption rate (OCR) 269 using Seahorse analysis. We found that, in the absence of ACOD1, BMDM treated for 270 12 h with IMQ had higher maximal respiration rate compared to the IMQ-treated WT BMDM (Fig. 6d). Consistent with this observation, IMQ-treated Acod1<sup>-/-</sup> BMDM had 271 272 enhanced mitochondrial ROS (mROS) synthesis compared to the IMQ-treated WT 273 BMDM (Fig. 6e). In contrast, glycolysis, was decreased at 24 h of IMQ treatment (Fig. 274 6f). These results support that endogenous itaconate modulates mitochondrial respiration 275 in myeloid cells, as proposed for exogenous itaconate (20).

276

277 Increased maximal mitochondrial respiration has been associated with mROS production 278 and oxidative stress during inflammatory conditions. To analyze the effect of ACOD1 279 absence in other myeloid cells, we tested the ability of BM-derived neutrophils to form 280 NETs, a feature that is dysregulated in murine and human lupus in association with aberrant mROS synthesis (2). Neutrophils from Acod1-/- mice treated with IMQ showed 281 282 no differences in their capacity to form NETs in response to a calcium-ionophore A23187 (Fig. 7a) However, Acod1<sup>-/-</sup> BM-derived neutrophils treated in vitro with ionophore A23187 283 displayed enhanced NET formation compared to the WT neutrophils (Fig. 7b). In vivo, 284 285 IMQ-treated BM neutrophils displayed enhanced mROS production compared to the WT

neutrophils (Fig. 7c). These data suggest that ACOD1/itaconate pathway attenuates
 neutrophil activation, NET formation and neutrophil mROS synthesis in response to TLR7
 stimulation.

289

#### 290 The ACOD1/itaconate pathway is associated with cardiometabolic parameters in

291 patients with SLE.

Given the association between ACOD1/itaconate levels and inflammation, we assessed plasma levels of itaconate in SLE patients and found them to be significantly reduced when compared with matched controls (**Fig. 8a**). To investigate the putative clinical relevance of itaconate levels in patients with SLE, correlation analyses were performed with clincail variables. We found a negative association between plasma itaconate levels and lupus disease activity, as measured by the SLE disease activity index (SLEDAI;

298 r=-0.359; p=0.013) and with levels of anti-dsDNA (-0.2, p=0.01). To investigate the 299 putative clinical relevance of itaconate levels with cardiovascular disease in patients with 300 SLE, correlation analyses were performed with various cardiometabolic parameters and 301 assessment of vascular function, vascular wall inflammation and coronary artery plague. 302 The following parameters were analyzed: arterial stiffness (measured by the cardio-ankle 303 vascular index (CAVI), endothelium-dependent vasorelaxation (measured by reactive 304 hyperemia index (RHI), coronary plaque burden (assessed by coronary CT), vascular wall 305 inflammation (with FDG/PET CT), insulin resistance (assessed by HOMA-IR) and other 306 cardiometabolic parameters, including high density lipoprotein levels and function. The 307 analysis showed that, while itaconate levels positively correlated with arterial stiffness 308 (Fig. 8b) and negatively correlated with endothelium-dependent vasorelaxation (Fig. 8c),

there was a positive association between itaconate levels and higher cholesterol efflux capacity, a marker of atheroprotective HDL function that is typically perturbed in lupus (**Fig. 8e**) and with lower non-calcified coronary plaque burden (NCB) (**Fig. 8d**), body mass index (BMI; **Fig. 8f**), aortic wall inflammation (avg TBR; **Fig. 8g**) and insulin resistance (HOMA-IR (**Fig.8h**)). These results suggest that dysregulation in itaconate levels in SLE is associated with markers of vascular inflammation and metabolic dysregulation.

#### 316 **Discussion**

317

318 We previously reported that administration of exogenous itaconate derivatives in the 319 NZB/W F1 mouse model of lupus improves clinical and immunologic features of this 320 disease(20). We have now expanded our investigations on the putative roles of the 321 endogenous ACOD1/ itaconate pathway in mouse and human lupus. Of note, itaconate 322 levels were found to be decreased in SLE compared to healthy individuals, in association 323 clinical, vascular and cardiometabolic parameters, suggesting that with specific 324 dysregulation of this pathway is operational in human disease. We have investigated the 325 role of ACOD1 (the enzyme responsible for itaconate production) in the development of 326 systemic autoimmunity in an induced murine lupus model. We had hypothesized that 327 ACOD1 deficiency would promote immune dysregulation and systemic inflammation in SLE. Consistent with our hypothesis, Acod1<sup>-/-</sup> mice exposed to a TLR7 agonist, a lupus 328 relevant stimulus, displayed disruptions in the splenic architecture, increased serum anti-329 330 dsDNA and IL-6, higher kidney immune complex deposition and proteinuria, when 331 compared to the WT IMQ-treated mice. These findings suggest that therapeutic strategies 332 enhancing the ACOD1/itaconate pathway or administration of itaconate derivatives as 333 anti-inflammatory agents could be useful in treating lupus and its associated organ 334 complications.

335

Various factors have been shown to induce the production of ACOD1/itaconate in macrophages and DCs, including LPS(<u>15</u>, <u>29</u>), viral and bacterial infections (<u>13</u>) and cytokine stimulation (including type I IFNs) (<u>29</u>). In this regard, we found that ACOD1 is

induced in vitro at the mRNA and protein levels in BMDM stimulated with a TLR7 agonist. Further, ACOD1 induction by TLR7 stimulation is partly dependent on type I IFNdependent signaling, which is consistent with other studies that have shown ACOD1 induction after IFN- $\beta$  treatment in macrophages.(<u>29</u>, <u>30</u>).

343

344 Recently, the role of macrophages in SLE pathogenesis has gained attention, with a focus 345 on how macrophage polarization may influence disease development. Abnormalities in 346 SLE patients, such as increased levels of type I IFNs, anti-dsDNA, IgG antibodies, NETs, 347 alarmins and mtDNA can skew macrophage polarization towards an M1 phenotype, 348 promoting an hyperinflammatory state and negatively influencing phagocytosis of 349 apoptotic cells (1, <u>31-33</u>). This M1-like macrophage association and its inflammatory 350 mediators have also been observed in SLE-associated atherosclerosis (34). However, in 351 one of the most severe manifestations of lupus, lupus nephritis (LN), it has been 352 suggested that the most predominant macrophage phenotype is the M2-like phenotype 353 (35). Macrophage polarization experiments showed that ACOD1 is expressed only in 354 human M2-like macrophages following 12 hours of TLR7 stimulation, with no induction 355 observed in M1-like macrophages. It is possible that low serum levels of itaconate in SLE 356 patients could be due, at least in part, to an increase in non-itaconate producing 357 macrophages (M1-like macrophages) versus M2-like. Consistent with this idea, serum 358 levels of the chemokine CCL5, known for inducing macrophage polarization toward an 359 M2-like phenotype (36) were also decreased in the serum of IMQ-treated  $Acod1^{-/-}$  mice 360 compared to the IMQ-treated WT mice. These observations require further investigation 361 to be able to conclude that they indeed play a role in modulation of itaconate levels in

SLE. Indeed, we do not rule out that the differential itaconate production in SLE patients 362 363 could be related to a decrease in ACOD1 catalytic activity (9). Eight active-site residues 364 critical for ACOD1 function have been previously identified (37), with six being classified 365 as very rare and to directly affect active site residues. Along with this idea, severely 366 affected male COVID-19 patients carrying loss-of-function TLR7 variants exhibit 367 decreased levels of ACOD1 mRNA (38). Therefore, understanding the polarization and 368 plasticity of macrophages, together with identification of possible variants in SLE that may 369 be involved in itaconate activity and synthesis would be important in understanding 370 perturbances in immunometabolism, with potential therapeutic implications. This hypothesis requires further investigation. 371

372

373 TLR agonists activate diverse signaling pathways including NF- $\kappa$ B, MAPKs, JAK/STAT, 374 and induction of epigenetic modifications (39). Using different signaling inhibitors, we 375 found that the ability of TLR7 agonists to induce ACOD1 in human macrophages was 376 dependent on NF-KB and MAPK activation. Inhibition of histone acetyl-transferase II also 377 decreased ACOD1 expression, suggesting that epigenetic changes are involved in 378 ACOD1 induction following TLR7 stimulation. Consistent with our observation in BMDM, 379 inhibition of the STING pathway and STAT3/STAT4 also decreased ACOD1 induction. 380 These results are in agreement with previous reports where STING activation after TLR4 381 engagement induces ACOD1 expression (40).

SLE is a multisystem disease, and its clinical manifestations vary according to the organs involved . We found disruptions in the splenic architecture of the IMQ-treated  $Acod1^{-/-}$ animals. Given that most immune cell subsets in spleen did not significantly change, it

remains to be further determined the mechanisms by which congestion and atrophy are induced, and the functional effects of these abnormalities. Of note, similar findings in the splenic architecture have been reported in human SLE, which may indicate that dysregulation in immunometabolic pathways can contribute to altering the spleen microenvironment. (<u>41</u>, <u>42</u>). This requires further investigation in future studies.

390 The effects of ACOD1 absence were also observed in renal function, renal immune 391 complex deposition and in the levels of circulating autoantibodies. Increased immune 392 complex deposition could be the result of higher levels of anti-dsDNA autoantibodies. 393 Indeed, we previously found that 4-octyl itaconate inhibits in vitro B cell proliferation (20); 394 as such, it is possible that endogenous itaconate could have the same inhibitory effect on 395 B cells and plasma cells. It remains to be determined whether increased cell death leading 396 to autoAg generation may be seen when disruptions in endogenous itaconate pathway 397 are operational. However, the observation that NET formation is enhanced in the absence 398 of ACOD1 indicates that the enhanced deposition of immune complexes may be linked 399 to both enhanced autoAb and autoAg formation, at least in part, through neutrophil cell 400 death dysregulation.

401

The ACOD1/itaconate pathway has been previously described to modulate cytokine production, especially IL-6 and IL1 $\beta$  (<u>15</u>, <u>29</u>). Consistent with these reports, we found that *Acod1<sup>-/-</sup>* mice treated with IMQ have higher serum levels of IL-6, results that were consistent with the in vitro macrophage experiments we performed, where IL-6 levels in the supernatant of *Acod1<sup>-/-</sup>* BMDM treated with IMQ were higher compared to the control BMDM. While IL-1 $\beta$  has been reported to be upregulated in the absence of itaconate (<u>15</u>),

our results did not show significant differences in the serum levels of Acod1-<sup>/-</sup> mice treated 408 409 with IMQ compared to the WT mice IMQ treated. In contrast, in vitro Acod1-- BMDM 410 treated with IMQ have higher levels of IL-1 $\beta$ , which is consistent with other in vitro reports 411 where absence of ACOD1/Itaconate increase levels of IL-1 $\beta$  (15). The modulation of 412 cytokines by the ACOD1/itaconate pathway may be context-dependent, influenced by 413 factors such as the specific cell type, the environment, or the signaling pathways involved. 414 Other factors in the in vivo setting, such as interaction with different cell types, the overall 415 immune response, or compensatory mechanisms could contribute to the observed 416 differences between in vivo and in vitro results.

417

Neutrophils express ACOD1 and produce itaconate under inflammatory conditions (<u>43</u>). Dysregulated neutrophils have a pathogenic role in SLE (<u>44</u>) and we found that, in the absence of ACOD1, there is enhanced NET formation and enhanced mROS synthesis in TLR7-induced lupus, implicating ROS dysregulation contributing to this phenomenon, as previously described by our group (<u>2</u>). These results are consistent with the recent report that exogenously added 4-OI diminishes formation of NETs by neutrophils of either normal (lean) or obese mice (<u>45</u>).

425

426 Noncalcified plaque burden (NCB) significantly increases the risk of plaque vulnerability 427 and rupture as well as the occurrence of acute coronary syndromes (46). Elevated NCB, 428 coupled with intensified arterial wall inflammation, has been linked to a higher prevalence 429 of high-risk plaques in individuals with psoriasis (47). In our study, we found that levels of 430 itaconate in lupus patients negatively correlate with NCB, vascular wall inflammation and

431 insulin resistance, while positively associating with atheroprotective HDL function. These 432 observations implicate alterations in the itaconate pathway potentially playing a role in 433 enhanced vascular risk in SLE, an area that requires further investigation. The findings 434 that vascular stiffness and impaired vascular function associated with itaconate levels 435 appears counterintuitive considering the potentially protective roles in other features of 436 vascular disease, including coronary atherosclerosis and various cardiometabolic 437 parameters. One possibility is differential roles of the ACOD1/itaconate pathway in 438 macrophages and other vascular cells. For example, exogenous analogs of itaconate can 439 inhibit angiogenesis, which could have a deleterious impact in conditions such as SLE. 440 where impaired angiogenesis has been reported (48, 49). It is also possible that the levels 441 of itaconate in association with endothelial dysfunction represent a counter-regulatory 442 function of this pathway to regulate vascular health. Indeed, we found low levels of VEGFA in the serum of IMQ-treated Acod1<sup>-/-</sup> compared to the IMQ-treated WT mice, 443 444 which is consistent with recent reports where itaconic acid raises VEGF protein levels in 445 skin and the number of CD31-positive vessels (50). Future studies should explore these 446 different hypotheses.

447

Limitations of this study include the use of a single mouse model of lupus. However, our previous observations that exogenous analogs of itaconate can improve NZB/W F1, another lupus mouse model, and that levels of ACOD1 decrease in these genetically prone mouse model as nephritis progresses, suggests that these observations are not model-dependent. Nevertheless, future studies should expand our observations into other lupus models as well as other autoimmune disorders. In addition, longitudinal

454 assessments of the cardiometabolic parameters and vascular damage progression in
455 SLE patients will be warranted to further establish the role of itaconate in modulating
456 vascular disease in this disease.

457

- 458 In conclusion, the results from these studies implicate the ACOD1/itaconate pathway in
- the pathogenesis of SLE and its associated organ damage and indicate that strategies to
- 460 target aberrant immunometabolism in autoimmunity could have positive therapeutic
- 461 implications, including a potential role in decreasing organ damage in these devastating
- 462 conditions.

464

#### 465 **Author contribution**

- 466 EPM and MJK conceived the study, designed experiments, and wrote the manuscript.
- 467 EPM, SN, LPB, DC, EB, BS, MASB, CCR and AR performed experiments; KJ, FN, SdO,
- 468 and SB, performed RNA-seq and analysis. ZXY performed histopathologic analysis; YTO
- 469 contributed patient recruitment and assessment, MD and SH contributed patient
- 470 evaluation and characterization, MN performed vascular function studies, ZM contributed
- 471 patient database management, NM contributed study design of vascular studies. EPM
- 472 analyzed the data and generated the graphs and stats shown in this work.

#### 473 Acknowledgments

We thank the Office of Science and Technology, Intramural Research Program,
NIAMS/NIH for technical support. We also thank Dr. Kwangwoo Kim (NIAMS/NIH) for
helpful discussions. This study was supported by the Intramural Research Program,
NIAMS/NIH (ZIA AR041199).

478

#### 480 **References**

481 1. Li H, et al. Interferon-induced mechanosensing defects impede apoptotic cell
482 clearance in lupus. J Clin Invest. 2015;125(7):2877-90.

483 2. Lood C, et al. Neutrophil extracellular traps enriched in oxidized mitochondrial DNA
484 are interferogenic and contribute to lupus-like disease. Nat Med. 2016;22(2):146-53.

485 3. Frostegård J. Systemic lupus erythematosus and cardiovascular disease. J Intern
486 Med. 2023;293(1):48-62.

487 4. Mendoza-Pinto C, et al. Endothelial dysfunction and arterial stiffness in patients
488 with systemic lupus erythematosus: A systematic review and meta-analysis.
489 Atherosclerosis. 2020;297:55-63.

490 5. Lightfoot YL, et al. Metabolic abnormalities and oxidative stress in lupus. Curr Opin
491 Rheumatol. 2017;29(5):442-9.

Blanco LP, et al. Improved Mitochondrial Metabolism and Reduced Inflammation
 Following Attenuation of Murine Lupus With Coenzyme Q10 Analog Idebenone. Arthritis
 Rheumatol. 2020;72(3):454-64.

495 7. Jamal Uddin M, et al. IRG1 induced by heme oxygenase-1/carbon monoxide
496 inhibits LPS-mediated sepsis and pro-inflammatory cytokine production. Cell Mol
497 Immunol. 2016;13(2):170-9.

498 8. Lee CG, et al. Cloning and analysis of gene regulation of a novel LPS-inducible
499 cDNA. Immunogenetics. 1995;41(5):263-70.

500 9. Michelucci A, et al. Immune-responsive gene 1 protein links metabolism to 501 immunity by catalyzing itaconic acid production. Proc Natl Acad Sci U S A. 502 2013;110(19):7820-5.

503 10. Wu R, et al. ACOD1 in immunometabolism and disease. Cell Mol Immunol. 504 2020;17(8):822-33.

505 11. Lampropoulou V, et al. Itaconate Links Inhibition of Succinate Dehydrogenase with
 506 Macrophage Metabolic Remodeling and Regulation of Inflammation. Cell Metab.
 507 2016;24(1):158-66.

508 12. Ogger PP, et al. Itaconate controls the severity of pulmonary fibrosis. Sci Immunol.509 2020;5(52).

510 13. Nair S, et al. Irg1 expression in myeloid cells prevents immunopathology during M.
511 tuberculosis infection. J Exp Med. 2018;215(4):1035-45.

512 14. Weiss JM, et al. Itaconic acid mediates crosstalk between macrophage 513 metabolism and peritoneal tumors. J Clin Invest. 2018;128(9):3794-805.

514 15. Bambouskova M, et al. Itaconate confers tolerance to late NLRP3 inflammasome
515 activation. Cell Rep. 2021;34(10):108756.

516 16. Peace CG, O'Neill LA. The role of itaconate in host defense and inflammation. J 517 Clin Invest. 2022;132(2).

518 17. Li R, et al. 4-OI Attenuates Carbon Tetrachloride-Induced Hepatic Injury via
519 Regulating Oxidative Stress and the Inflammatory Response. Front Pharmacol.
520 2021;12:651444.

521 18. Tian F, et al. 4-Octyl itaconate protects against renal fibrosis via inhibiting TGF522 β/Smad pathway, autophagy and reducing generation of reactive oxygen species. Eur J
523 Pharmacol. 2020;873:172989.

524 19. Xin Y, et al. 4-Octyl itaconate (4-OI) attenuates lipopolysaccharide-induced acute
525 lung injury by suppressing PI3K/Akt/NF-κB signaling pathways in mice. Exp Ther Med.
526 2021;21(2):141.

527 20. Blanco LP, et al. Modulation of the Itaconate Pathway Attenuates Murine Lupus.
528 Arthritis Rheumatol. 2022;74(12):1971-83.

529 21. Tang C, et al. 4-Octyl Itaconate Activates Nrf2 Signaling to Inhibit Pro-Inflammatory
530 Cytokine Production in Peripheral Blood Mononuclear Cells of Systemic Lupus
531 Erythematosus Patients. Cell Physiol Biochem. 2018;51(2):979-90.

532 22. Li Y, et al. Lipidomic and metabolomic profiling reveals novel candidate biomarkers
533 in active systemic lupus erythematosus. Int J Clin Exp Pathol. 2019;12(3):857-66.

534 23. Yokogawa M, et al. Epicutaneous application of toll-like receptor 7 agonists leads
535 to systemic autoimmunity in wild-type mice: a new model of systemic Lupus
536 erythematosus. Arthritis Rheumatol. 2014;66(3):694-706.

537 24. Simón-Fuentes M, et al. TLR7 activation in M-CSF-dependent monocyte-derived 538 human macrophages potentiates inflammatory responses and prompts neutrophil 539 recruitment. J Innate Immun. 2023;15(1):517-30.

540 25. Kawasaki T, Kawai T. Toll-like receptor signaling pathways. Front Immunol. 541 2014;5:461.

542 26. Han J, et al. Life-threatening spontaneous splenic rupture with systemic lupus 543 erythematosus: case report and literature review. Clin Rheumatol. 2012;31(6):1019-25.

544 27. Wang X, et al. Effects of Gasdermin D in Modulating Murine Lupus and its 545 Associated Organ Damage. Arthritis Rheumatol. 2020;72(12):2118-29.

546 28. Ryan H, et al. Vascular Inflammation in Mouse Models of Systemic Lupus 547 Erythematosus. Front Cardiovasc Med. 2022;9:767450.

548 29. Mills EL, et al. Itaconate is an anti-inflammatory metabolite that activates Nrf2 via 549 alkylation of KEAP1. Nature. 2018;556(7699):113-7.

30. Tallam A, et al. Gene Regulatory Network Inference of Immunoresponsive Gene 1
(IRG1) Identifies Interferon Regulatory Factor 1 (IRF1) as Its Transcriptional Regulator in
Mammalian Macrophages. PLoS One. 2016;11(2):e0149050.

553 31. Caielli S, et al. Erythroid mitochondrial retention triggers myeloid-dependent type I 554 interferon in human SLE. Cell. 2021;184(17):4464-79.e19.

32. Kahlenberg JM, et al. Neutrophil extracellular trap-associated protein activation of
the NLRP3 inflammasome is enhanced in lupus macrophages. J Immunol.
2013;190(3):1217-26.

33. Schaper F, et al. High mobility group box 1 skews macrophage polarization and
negatively influences phagocytosis of apoptotic cells. Rheumatology (Oxford).
2016;55(12):2260-70.

561 34. Al Gadban MM, et al. Accelerated vascular disease in systemic lupus 562 erythematosus: role of macrophage. Clin Immunol. 2015;157(2):133-44.

35. Olmes G, et al. CD163+ M2c-like macrophages predominate in renal biopsies from
patients with lupus nephritis. Arthritis Res Ther. 2016;18:90.

36. Zhuang Y, et al. Blocking the CCL5-CCR5 Axis Using Maraviroc Promotes M1
Polarization of Macrophages Cocultured with Irradiated Hepatoma Cells. J Hepatocell
Carcinoma. 2021;8:599-611.

37. Chen F, et al. Crystal structure of cis-aconitate decarboxylase reveals the impact
of naturally occurring human mutations on itaconate synthesis. Proc Natl Acad Sci U S
A. 2019;116(41):20644-54.

571 38. Mantovani S, et al. Rare variants in Toll-like receptor 7 results in functional 572 impairment and downregulation of cytokine-mediated signaling in COVID-19 patients. 573 Genes Immun. 2022;23(1):51-6.

574 39. O'Neill LA, Bowie AG. The family of five: TIR-domain-containing adaptors in Toll-575 like receptor signalling. Nat Rev Immunol. 2007;7(5):353-64.

576 40. Chen F, et al. The STING1-MYD88 complex drives ACOD1/IRG1 expression and 577 function in lethal innate immunity. iScience. 2022;25(7):104561.

578 41. Karassa FB, Isenberg DA. Spontaneous rupture of the spleen: an unusual 579 complication of systemic lupus erythematosus. Lupus. 2001;10(12):876-8.

580 42. Krauser RE. Spontaneous rupture of the spleen in systemic lupus erythematosus.
581 Jama. 1976;236(10):1149.

582 43. Zhao Y, et al. Neutrophils resist ferroptosis and promote breast cancer metastasis
583 through aconitate decarboxylase 1. Cell Metab. 2023;35(10):1688-703.e10.

584 44. Clarke J. Pathogenicity of neutrophils linked to maturation stage in SLE. Nat Rev585 Rheumatol. 2020;16(2):63.

45. Burczyk G, et al. Itaconate Suppresses Formation of Neutrophil Extracellular Traps
(NETs): Involvement of Hypoxia-Inducible Factor 1α (Hif-1α) and Heme Oxygenase (HO1). Front Immunol. 2022;13:864638.

589 46. van Velzen JE, et al. Comparison of the relation between the calcium score and 590 plaque characteristics in patients with acute coronary syndrome versus patients with 591 stable coronary artery disease, assessed by computed tomography angiography and 592 virtual histology intravascular ultrasound. Am J Cardiol. 2011;108(5):658-64.

593 47. Naik HB, et al. Severity of Psoriasis Associates With Aortic Vascular Inflammation
594 Detected by FDG PET/CT and Neutrophil Activation in a Prospective Observational
595 Study. Arterioscler Thromb Vasc Biol. 2015;35(12):2667-76.

596 48. Kahlenberg JM, et al. Inflammasome activation of IL-18 results in endothelial
597 progenitor cell dysfunction in systemic lupus erythematosus. J Immunol.
598 2011;187(11):6143-56.

599 49. Vidal I, et al. The Immunomodulator Dimethyl Itaconate Inhibits Several Key Steps
600 of Angiogenesis in Cultured Endothelial Cells. Int J Mol Sci. 2022;23(24).

50. Luo G, et al. Itaconic acid induces angiogenesis and suppresses apoptosis via
Nrf2/autophagy to prolong the survival of multi-territory perforator flaps. Heliyon.
2023;9(7):e17909.

#### 604 Figure legends

605 Fig. 1 ACOD1 is induced after TLR7 activation in BMDM. a) Western blot showing ACOD1 protein 606 expression in WT and Acod1<sup>-/-</sup> BMDM treated with imiguimod (1 µg/mL) at 0, 3, 12 and 24 hours. b) Western blot showing ACOD1 protein expression evaluated in WT, Acod1-/-, and Ifnar1-/- BMDM treated in vitro with 607 608 imiguimod (1 ug/mL) for 0, 12 and 24 hours, RNA seg was performed in BMDM treated with IMQ for 12h. 609 c) Heatmap representation of the genes induced in BMDM after 12h of IMQ stimulation. d) Gene ontology 610 analysis of genes differentially expressed between control BMDM and IMQ treated BMDM. e) Heatmap 611 representation of the genes associated to metabolic pathways in BMDM after 12h of IMQ stimulation. RNA-612 seq data was analyzed with DESeq2. The log-transformed DESeq2-normalized read counts were further 613 scaled for each gene individually using the mean expression levels and their corresponding standard 614 deviations to facilitate visualization in a heatmap. Three blots were processed in parallel for a and b, n = 3. 615 Six independent mice were chosen from each genotype for c, d, and e. n = 6.

616

617 Fig.2 ACOD1 is induced after TLR7 activation in human MDM a) Western blot showing ACOD1 618 expression in GM and M (GM- and M-CSF, respectively) human MDM (Macrophages Derived from 619 Monocytes) after 12 h of treatment with LPS 100 ng/uL or IMQ 1 µg/mL. b) Western blot showing basal 620 expression of TLR4 and TLR7 in GM and M MDM. c) Western blot and d) densitometry results showing 621 ACOD1 expression in M MDM after TLR7 activation in the presence of different signaling inhibitors. Bay 10 622 μM (NF-κB), BIRB 0.1 μM (p38), SP600125 30 μM (JNK), U0126 2.5 μM (ERK1/2), SH-4-54 5 μM 623 (STAT3/STAT5), H-151 1 μg/mL (STING), HAT Inh II 5 μM (HAT II), Trichostatin A (TSA) 5 μM (HDAC 624 inhibitor) Graphs show the mean  $\pm$  SEM, % of expression is relative to the IMQ 12h without inhibitor. n = 3, 625 Three blots were processed in parallel for a and c. The statistical analysis was done using Mann-Whitney 626 test, \*: p<0.05, \*\*: p<0.01; \*\*\*: p<0.005.

627

628 Fig. 3 IMQ treated Acod1<sup>-/-</sup> mice display disruptions in splenic architecture and increases in naïve 629 B cells compared to the IMQ-treated WT mice. Wild type (WT) and Acod1<sup>-/-</sup> mice (8–10-week-old female) 630 were treated with 5% imiguimod cream epicutaneously 3 times per week for 5 weeks, to induce a lupus 631 phenotype. a) Survival curves for WT and  $Acod1^{-l-}$  mice during several weeks of imiquimod treatment, n =632 10. b) Spleen weight and spleen:body weight ratio in untreated and IMQ treated WT and Acod1<sup>-/-</sup> mice, n 633 = 28. c) Spleen H&E staining in formalin-fixed, paraffin-embedded (FFPE) from WT and Acod1<sup>-/-</sup> mice after 634 IMQ treatment, n = 10. Pathology scores of spleen congestion and atrophy were as follows: no changes = 635 0, mild changes = 1, moderate changes = 2, and severe changes = 3. d) Splenocytes from untreated and 636 IMQ-treated WT and  $Acod1^{-/-}$  mice were analyzed by flow cytometry to quantify % of monocytes, DC, 637 neutrophils and B cell populations. Nontreated conditions, n = 8, IMQ-treated conditions, n = 18. Graphs 638 show the mean ± SEM. The statistical analysis was done using Mann-Whitney test, \*:p<0.05, \*\*: p<0.01. 639

- 640 Fig. 4 Acod1<sup>-/-</sup> mice treated with IMQ have higher levels of serum anti-ds-DNA, renal immune 641 complex deposition and albuminuria. a) Serum levels of total IgG and antibodies against Sm, RNP and 642 dsDNA analyzed by ELISA, untreated conditions, n = 6, IMQ-treated, n = 26, b) Representative immunofluorescence photomicrographs displaying renal immune complex deposition. IgG is depicted in 643 644 red, C3 in green, and nuclei in blue. Original magnification 40x. c) Quantification of pixel analysis of 645 glomeruli in 5 different WT or  $Acod1^{-1}$  IMQ-treated using ImageJ. n = 5 d) Analysis of proteinuria in mice at 646 the time of euthanasia, n = 7. Albumin was quantified by ELISA and Creatinine by colorimetric assay; then 647 albumin/creatinine ratios were calculated. d) Acod1 mRNA expression in kidney from spontaneous lupus 648 mice NZBW at 10, 20 and 30 weeks old, n = 3. Graphs show the mean ± SEM. Graph in a, c, and e the 649 statistical analysis was done using Mann-Whitney test, \*:p<0.05, \*\*: p<0.01. In d, Student's t test analysis 650 was performed. \*:p<0.05.
- 651

652 Fig. 5 IMQ treated Acod1<sup>-/-</sup> mice have decreased serum levels of CCL5 and VEGFA, while IL-6 serum

**levels are increased.** Detection of various cytokines and chemokines in the serum of WT and  $Acod1^{-1/2}$ mice treated with IMQ. The graphs show the levels for a) IL-1 $\beta$ , b) IL-18, c) IL-6, d) CCL5, and e) VEGFA.

655 Untreated conditions, n = 6, IMQ-treated conditions n = 26. Graphs show the mean ± SEM. The statistical analysis was done using Student's t test, \*:p<0.05, \*\*\*:p<0.005. For CCL5 and VEGFA, IMQ-treated values

were adjusted for the untreated values, given that there was a trend for untreated Kos to have lower levelsof VEGFA and CCL5.

659

660 Fig. 6 Acod1<sup>-/-</sup> BMDM treated with IMQ display differential levels of proinflammatory cytokines and 661 chemokines and higher mROS production. WT and Acod1<sup>-/-</sup> BMDM were treated with IMQ or left 662 intrerated **a**) after 12 h of stimulation gene expression was measured by qPCR (n =  $\beta$ ). Data were 663 normalized to untreated mice. Data are represented as mean ± SEM. b) Western blot showing pro-IL1 664 levels in BMDM from three different WT and Acod1<sup>-/-</sup> mice treated with IMQ 1 µg/mL for 24 h. n = 3. c) IL-665  $1\beta$ , IL-6 and TNF- $\alpha$  in the supernatants from WT and Acod1<sup>-/-</sup> BMDM treated with IMQ 1 µg/mL for 24 h. Results are from 4 independent experiments. n = 20. d) Seahorse Mitochondrial stress test analysis (n = 666 15) and e) mitoROS production (mitosox) of WT and Acod1-/- BMDM treated or not with IMQ 1 µg/mL for 667 668 12h. (n = 15) f) glycolysis stress test analysis of WT and  $Acod1^{-h}$  BMDM treated or not with IMQ 1 µg/mL 669 for 24 h (n = 15). The statistical analysis was done using Mann-Whitney test, \*:p<0.05, \*:p<0.01. 670

671 Fig. 7 Compared to WT, Acod1<sup>-/-</sup> BM neutrophils have higher NET formation and mitoROS production. a) NETs were quantified in BM neutrophils from mice treated with IMQ (in vivo treated) and b) 672 673 BM neutrophils treated in vitro with IMQ 1 µg/mL (in vitro treated), 2 hours post-plating, by Sytox and 674 PicoGreen plate assay to measure external and total DNA, respectively n = 9. c) Mitochondrial reactive 675 oxygen species (mROS) were quantified 1-hour post-plating, using MitoSox. n = 9. Graphs show the mean 676 SEM. The statistical analysis done usina Mann-Whitney ± was test. 677 \*:p<0.05,\*\*:p<0.01;\*\*\*:p<0.005;\*\*\*\*p<0.001.

678

**Fig. 8. Association between cardiometabolic parameters and itaconate levels in serum in SLE and healthy controls. SLE** a) Levels of itaconate were measured in plasma samples from SLE patients (n=31) and control (n=17). Results represent mean +/- SEM. Mann Whitney analysis was used. \*\*\*p< 0.001. Levels of itaconate measured in SLE plasma were correlated with b) cardio-ankle vascular index (CAVI), c) reactive hyperemia index (RHI), d) non calcified coronary plaque burden (NCB), e) plasma cholesterol efflux capacity (measure of HDL function), f) body mass index (BMI), g) vascular wall inflammation (TB) and h) Insulin resistance (HOMA-IR). Spearman correlation was used.



.

# 692 Figure 2

c)



d)



696 Figure 3







# 698 **Figure 4**



Mouse kidney NZBW mice

# 700 Figure 5



# 731 Figure 6



# 733 Figure 7



# 736 Figure 8

